<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Aoki T</submitter><funding>Japan Society for the Promotion of Science London</funding><funding>Japanese Leukemia Research Fund</funding><funding>Masato Kawano Memorial Public Interest Foundation for Promotion of Pediatrics</funding><funding>Chiba University</funding><funding>Japan Society for the Promotion of Science</funding><pagination>2223-2233</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7385353</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>111(7)</volume><pubmed_abstract>Invariant natural killer T (iNKT) cells are innate-like CD1d-restricted T cells that express the invariant T cell receptor (TCR) composed of Vα24 and Vβ11 in humans. iNKT cells specifically recognize glycolipid antigens such as α-galactosylceramide (αGalCer) presented by CD1d. iNKT cells show direct cytotoxicity toward CD1d-positive tumor cells, especially when CD1d presents glycolipid antigens. However, iNKT cell recognition of CD1d-negative tumor cells is unknown, and direct cytotoxicity of iNKT cells toward CD1d-negative tumor cells remains controversial. Here, we demonstrate that activated iNKT cells recognize leukemia cells in a CD1d-independent manner, however still in a TCR-mediated way. iNKT cells degranulated and released Th1 cytokines toward CD1d-negative leukemia cells (K562, HL</pubmed_abstract><journal>Cancer science</journal><pubmed_title>Activated invariant natural killer T cells directly recognize leukemia cells in a CD1d-independent manner.</pubmed_title><pmcid>PMC7385353</pmcid><funding_grant_id>Therapeutics Research Initiative Grant/2018-Y7,</funding_grant_id><funding_grant_id>Therapeutics Research Initiative Grant/2018‐Y7,</funding_grant_id><funding_grant_id>Research award for young researchers</funding_grant_id><funding_grant_id>KAKENHI/18K16108</funding_grant_id><pubmed_authors>Hara A</pubmed_authors><pubmed_authors>Takatani T</pubmed_authors><pubmed_authors>Motoyoshi K</pubmed_authors><pubmed_authors>Kiuchi M</pubmed_authors><pubmed_authors>Motohashi S</pubmed_authors><pubmed_authors>Shimojo N</pubmed_authors><pubmed_authors>Ishii A</pubmed_authors><pubmed_authors>Takami M</pubmed_authors><pubmed_authors>Nakayama T</pubmed_authors><pubmed_authors>Hino M</pubmed_authors><pubmed_authors>Aoki T</pubmed_authors><pubmed_authors>Toyoda T</pubmed_authors><pubmed_authors>Okada R</pubmed_authors><pubmed_authors>Hirahara K</pubmed_authors><pubmed_authors>Koyama-Nasu R</pubmed_authors><pubmed_authors>Kimura MY</pubmed_authors></additional><is_claimable>false</is_claimable><name>Activated invariant natural killer T cells directly recognize leukemia cells in a CD1d-independent manner.</name><description>Invariant natural killer T (iNKT) cells are innate-like CD1d-restricted T cells that express the invariant T cell receptor (TCR) composed of Vα24 and Vβ11 in humans. iNKT cells specifically recognize glycolipid antigens such as α-galactosylceramide (αGalCer) presented by CD1d. iNKT cells show direct cytotoxicity toward CD1d-positive tumor cells, especially when CD1d presents glycolipid antigens. However, iNKT cell recognition of CD1d-negative tumor cells is unknown, and direct cytotoxicity of iNKT cells toward CD1d-negative tumor cells remains controversial. Here, we demonstrate that activated iNKT cells recognize leukemia cells in a CD1d-independent manner, however still in a TCR-mediated way. iNKT cells degranulated and released Th1 cytokines toward CD1d-negative leukemia cells (K562, HL</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Jul</publication><modification>2025-04-04T07:40:40.188Z</modification><creation>2025-04-04T07:40:40.188Z</creation></dates><accession>S-EPMC7385353</accession><cross_references><pubmed>32324315</pubmed><doi>10.1111/cas.14428</doi></cross_references></HashMap>